Subcutaneous Injection

TOKYO, Japan & CAMBRIDGE, Mass., July 13, 2026 Eisai Co., Ltd. and Biogen Inc. have achieved a major regulatory...

PARIS | June 19, 2026 Sanofi announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the...

TOKYO and CAMBRIDGE, Mass., May 8, 2026 Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and...

Thousand Oaks, California, USA, April 6, 2026 Phase 3 Success Expands TEPEZZA Treatment Options In a major advancement for...

Paris, France | March 27, 2026 CHMP Recommends Innovative Subcutaneous Formulation Sanofi has achieved a major regulatory milestone as...

Tokyo & Cambridge, Massachusetts, January 25, 2026 — Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food...

MUMBAI, India, September 5, 2025 — Glenmark Pharmaceuticals has announced the initiation of a multi-country Phase 3 clinical trial...

Eisai Co., Ltd. and Biogen Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved LEQEMBI®...